山東(dong)(dong)金(jin)城(cheng)醫(yi)(yi)藥(yao)(yao)集團股(gu)份(fen)有(you)(you)(you)限公(gong)(gong)司(si)(簡稱(cheng)“金(jin)城(cheng)醫(yi)(yi)藥(yao)(yao)”,股(gu)票代碼:300233)成立于(yu)2004年,創業(ye)(ye)(ye)(ye)(ye)(ye)板上市(shi)企業(ye)(ye)(ye)(ye)(ye)(ye)。目前,公(gong)(gong)司(si)擁有(you)(you)(you)北京朗依制(zhi)藥(yao)(yao)有(you)(you)(you)限公(gong)(gong)司(si)、上海金(jin)城(cheng)藥(yao)(yao)業(ye)(ye)(ye)(ye)(ye)(ye)有(you)(you)(you)限公(gong)(gong)司(si)、廣東(dong)(dong)金(jin)城(cheng)金(jin)素制(zhi)藥(yao)(yao)有(you)(you)(you)限公(gong)(gong)司(si)、山東(dong)(dong)金(jin)城(cheng)生物藥(yao)(yao)業(ye)(ye)(ye)(ye)(ye)(ye)有(you)(you)(you)限公(gong)(gong)司(si)、山東(dong)(dong)金(jin)城(cheng)醫(yi)(yi)藥(yao)(yao)化工有(you)(you)(you)限公(gong)(gong)司(si)、山東(dong)(dong)金(jin)城(cheng)石墨烯科技有(you)(you)(you)限公(gong)(gong)司(si)、意大利海寶(bao)露(lu)有(you)(you)(you)限責任公(gong)(gong)司(si)等(deng)18家參(can)控股(gu)公(gong)(gong)司(si)。公(gong)(gong)司(si)通過“實(shi)業(ye)(ye)(ye)(ye)(ye)(ye)+資本”雙輪驅動發(fa)展(zhan)模(mo)式,已構建形成獨具(ju)金(jin)城(cheng)特(te)色的醫(yi)(yi)藥(yao)(yao)健(jian)康制(zhi)藥(yao)(yao)工業(ye)(ye)(ye)(ye)(ye)(ye)產(chan)業(ye)(ye)(ye)(ye)(ye)(ye)鏈(lian),業(ye)(ye)(ye)(ye)(ye)(ye)務范圍涉及生物制(zhi)藥(yao)(yao)、頭孢類(lei)醫(yi)(yi)藥(yao)(yao)中間體、特(te)色原(yuan)料藥(yao)(yao)、終端制(zhi)劑(ji)、保(bao)健(jian)品(pin)、新材料等(deng)產(chan)業(ye)(ye)(ye)(ye)(ye)(ye)領域(yu),并(bing)現(xian)已形成年營業(ye)(ye)(ye)(ye)(ye)(ye)收入超20億(yi)元(yuan)、總資產(chan)近(jin)50億(yi)的產(chan)業(ye)(ye)(ye)(ye)(ye)(ye)規模(mo)。
山(shan)東金(jin)城醫藥集(ji)團(tuan)股份有(you)限公司是(shi)以(yi)三、四代(dai)頭(tou)孢類醫藥中間體(ti)(ti)、特色原料藥、生(sheng)物(wu)制藥、終端制劑以(yi)及婦兒產(chan)品(pin)(pin)(pin)等為主業(ye)(ye)(ye)的科研、生(sheng)產(chan)企業(ye)(ye)(ye),其中,頭(tou)孢類醫藥中間體(ti)(ti)產(chan)品(pin)(pin)(pin)銷量、銷售收入連續多年位居行業(ye)(ye)(ye)前列,是(shi)重要(yao)的生(sheng)物(wu)制藥生(sheng)產(chan)基(ji)地以(yi)及國內(nei)醫藥健康產(chan)業(ye)(ye)(ye)集(ji)團(tuan)。主導產(chan)品(pin)(pin)(pin)有(you)谷(gu)胱甘肽(花青肽美品(pin)(pin)(pin)牌)、硝(xiao)呋(fu)太爾(er)膠囊(朗依品(pin)(pin)(pin)牌)、富(fu)馬酸比索洛(luo)爾(er)膠囊(洛(luo)雅品(pin)(pin)(pin)牌)、牡(mu)蠣碳酸鈣(gai)咀嚼(jiao)片(pian)(金(jin)娃寧品(pin)(pin)(pin)牌)、復(fu)方木香鋁鎂片(pian)(德(de)瑞(rui)夫品(pin)(pin)(pin)牌)等近百種。
當前,公(gong)司堅持科(ke)(ke)學發展(zhan),按照“大健康(kang)、大醫藥(yao)(yao)(yao),打(da)造(zao)(zao)具有金城(cheng)特色(se)(se)制藥(yao)(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)(ye)鏈”的(de)產(chan)(chan)(chan)(chan)業(ye)(ye)定(ding)位和“調整、轉型(xing)、升級、發展(zhan)”的(de)戰(zhan)略思路,專(zhuan)注(zhu)專(zhuan)注(zhu)金城(cheng)特色(se)(se)制藥(yao)(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)(ye)鏈三大方向(xiang)建設(she)——“頭(tou)孢類抗(kang)生素終端(duan)制劑(ji)產(chan)(chan)(chan)(chan)業(ye)(ye)鏈,多肽類特色(se)(se)生物制藥(yao)(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)(ye)鏈和婦科(ke)(ke)、調節免疫制劑(ji)特色(se)(se)類產(chan)(chan)(chan)(chan)業(ye)(ye)鏈 ”。同時,公(gong)司加快(kuai)“三個平(ping)臺”建設(she)(技術創新平(ping)臺、產(chan)(chan)(chan)(chan)業(ye)(ye)運營平(ping)臺、組織管(guan)控(kong)平(ping)臺),加快(kuai)打(da)造(zao)(zao)“四支(zhi)隊(dui)伍(wu)”建設(she)(企業(ye)(ye)家隊(dui)伍(wu)、中(zhong)高層管(guan)理隊(dui)伍(wu)、專(zhuan)業(ye)(ye)人才隊(dui)伍(wu)、熟練工(gong)人隊(dui)伍(wu)),積極實踐(jian)內涵式(shi)(shi)發展(zhan)、外延式(shi)(shi)擴(kuo)張和投資并購三種發展(zhan)方式(shi)(shi),著力將公(gong)司打(da)造(zao)(zao)成“科(ke)(ke)技化、生態化、規范化、品(pin)牌化、國際化”的(de)現代化醫藥(yao)(yao)(yao)健康(kang)產(chan)(chan)(chan)(chan)業(ye)(ye)集團,助(zhu)推(tui)醫藥(yao)(yao)(yao)進步,創享(xiang)健康(kang)生活,志在成為醫藥(yao)(yao)(yao)健康(kang)產(chan)(chan)(chan)(chan)業(ye)(ye)創新型(xing)領(ling)軍企業(ye)(ye)。